$BCLI News

BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts As Board Director

Brainstorm Cell Q1 EPS $(0.19) Beats $(0.36) Estimate

Brainstorm Cell Q4 EPS $(0.20) Beats $(0.37) Estimate

Brainstorm Cell Therapeutics Secures Second $1 Million Strategic Placement; Total $2 Million Raised In February

Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing at Premium to Market

BrainStorm Cell Therapeutics Announces $1M Strategic Private Placement Priced At $0.60 Per Share With 120% Warrant Coverage At $1.00 To Support NurOwn Phase 3b ALS Trial And Regulatory Initiatives

BrainStorm Cell Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Brainstorm Cell Q3 EPS $(0.19) Beats $(0.37) Estimate

BCLI: Focused on Initiation of Phase 3b ENDURANCE Trial of NurOwn® in ALS…

Brainstorm Cell Therapeutics Inc. (BCLI) Q2 2025 Earnings Call Transcript

BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update

Brainstorm Cell Q2 EPS $(0.34) Beats $(0.37) Estimate

A Peek at Brainstorm Cell's Future Earnings

BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update

Maxim Group Downgrades Brainstorm Cell to Hold

BrainStorm Cell Therapeutics is trading lower after receiving a delisting notice from Nasdaq effective July 18, 2025.

Brainstorm Cell Therapeutics Crashes 42% After Voluntary Nasdaq Delisting Announcement

BrainStorm Cell Therapeutics Announces Nasdaq Delisting and Transition to OTCQB

BrainStorm Cell Therapeutics Receives Delisting Notice From Nasdaq Effective On July 18, 2025.

FDA Review of Citizen Petition Offers a Fresh Look at NurOwn®'s Evidence of Treatment Effectiveness